Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4644422 | 1.00 | HSD11B1 (0.32) | HSD11B1SMN1; SMN2 | |
| SCHEMBL4640246 | 1.00 | HSD11B1 (0.32) | HSD11B1SMN1; SMN2 | |
| SCHEMBL4640214 | 0.84 | PDE4D (0.33) | SMN1; SMN2 | |
| SCHEMBL4641185 | 0.84 | PDE4D (0.33) | SMN1; SMN2 | |
| SCHEMBL4640216 | 0.84 | PDE4D (0.33) | SMN1; SMN2 | |
| SCHEMBL3464258 | 0.82 | APLNR (0.31) | — | |
| SCHEMBL3464545 | 0.82 | APLNR (0.31) | — | |
| SCHEMBL3464261 | 0.82 | APLNR (0.31) | — | |
| SCHEMBL3464262 | 0.82 | APLNR (0.31) | — | |
| SCHEMBL3464548 | 0.82 | APLNR (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1958666-A1 | Heterocyclic-substituted alkanamides as therapeutic compounds | Speedel Experimenta AG (CH) | 2008-08-20 | — | — | EP | disclosed |
| US-20080176947-A1 | Heterocyclic-Substituted Alkanamides Useful as Renin Inhibitors | NOVARTIS AG (CH) | 2008-07-24 | — | — | US | disclosed |
| EP-1856032-A1 | HETEROCYCLIC-SUBSTITUTED ALKANAMIDES USEFUL AS RENIN INHIBITORS | Speedel Experimenta AG (CH) | 2007-11-21 | — | — | EP | disclosed |
| WO-2006095020-A1 | HETEROCYCLIC-SUBSTITUTED ALKANAMIDES USEFUL AS RENIN INHIBITORS | SPEEDEL EXPERIMENTA AG (CH) | 2006-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176947-A1 | Heterocyclic-Substituted Alkanamides Useful as Renin Inhibitors | REN, ACE, AGTR1 | HSD11B1 505/4885SMN1; SMN2 3172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.